Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

Bibliographic Details
Main Authors:	D. Lüftner, H. Tesch, M. Schmidt, A. Hartkopf, S. Streicher, A. Resch, L. Genovese, C. Rosé, R. Valenti, N. Harbeck
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000898

Similar Items

Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial
by: Joanne Mortimer, et al.
Published: (2019-02-01)

Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
by: M. Martin, et al.
Published: (2021-04-01)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
by: Stephen K. L. Chia, et al.
Published: (2019-03-01)

Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
by: R. Bartsch, et al.
Published: (2021-04-01)

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
by: Arlene Chan
Published: (2016-09-01)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
by: Sara Alkhezayem, et al.
Published: (2020-08-01)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
by: Kourie HR, et al.
Published: (2017-07-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: N. Harbeck
Published: (2021-04-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
by: Chilà G, et al.
Published: (2021-06-01)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and <i>HER2</i>-Mutated Breast Cancer
by: Denis M. Collins, et al.
Published: (2019-05-01)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
by: Jangsoon Lee, et al.
Published: (2021-06-01)

Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer
by: M. Ruiz-Borrego, et al.
Published: (2021-04-01)

(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study
by: R. Valenti, et al.
Published: (2021-04-01)

Neratinib protects pancreatic beta cells in diabetes
by: Amin Ardestani, et al.
Published: (2019-11-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
by: Laurence Booth, et al.
Published: (2019-07-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
by: Reva K. Basho, et al.
Published: (2018-05-01)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
by: Nadia Harbeck
Published: (2018-07-01)

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
by: Elizabeth M. Salvo, et al.
Published: (2021-06-01)

Neratinib-Induced Duodenal Ulcer: A Case Report
by: Bahar Moftakhar, et al.
Published: (2020-06-01)

Profile of neratinib and its potential in the treatment of breast cancer
by: Feldinger K, et al.
Published: (2015-06-01)

Analysis of two members of the EXT family, EXT1 and EXT2 bearing ER-, Golgi-, and secretory vesicle-sorting motifs
by: Lee, Tracy Phek Hui
Published: (2009)

Analysis of two members of the EXT family, EXT1 and EXT2 bearing ER-, Golgi-, and secretory vesicle-sorting motifs
by: Lee, Tracy Phek Hui
Published: (2009)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
by: Hong-Fei Gao, et al.
Published: (2021-10-01)

Ext and the square lemma.
by: Ching, Wai-Sin.
Published: (2009)

Exts and the AGT Relations
by: Negut, Andrei
Published: (2018)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
by: Serena Di Cosimo, et al.
Published: (2021-02-01)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
by: B. Porte, et al.
Published: (2020-12-01)

Recurrent and Metastatic Characteristics and Prognosis of Advanced HER2-positive Breast Cancer Patients with Different HR Status
by: REN Yulin, et al.
Published: (2019-01-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

Mutation spectrum of EXT1 and EXT2 in the Saudi patients with hereditary multiple exostoses
by: Zayed Al-Zayed, et al.
Published: (2021-02-01)

A Novel of neutrosophic τ -Structure Ring ExtB and ExtV Spaces
by: R. Narmada Devi
Published: (2020-03-01)

The roles of ext1 and ext2 in heparan sulfate polymerization and hereditary multiple exostoses
by: McCormick, Craig
Published: (2009)

The roles of ext1 and ext2 in heparan sulfate polymerization and hereditary multiple exostoses
by: McCormick, Craig
Published: (2009)

Effects of 5-HTâ‚‚, 5-HTâ‚ƒ and 5-HTâ‚„ ligands in the rodent elevated zero maze of anxiety
by: Gilmore, P. E.
Published: (2002)

Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
by: H. Rugo, et al.
Published: (2021-04-01)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA; Comment on “Ethics in HTA: Examining the ‘Need for Expansion’”
by: Anthony J. Culyer
Published: (2019-12-01)

Finiteness conditions on the Ext-algebra
by: Davis, Gabriel
Published: (2005)